NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

NWBO shareholders and patients are depending on the efforts an independent CDMO company is making to sort its highly complex manufacturing out. This is a risk no NWBO shareholder took into account when investing in NWBO. NWBO shareholders doing their due diligence did so on the likelihood the trial itself was going to be a success and the drug getting approval based on that. No NWBO shareholder contemplated the risk of DCVAXL NOT being able to get approval if Advent Ltd a Toucan subsidiary will not be able to get its MIA certificate.

All because of the greed of one person Linda Powers. Insane if you think about it. All could have been avoided if management stayed with CRL, the CDMO who got paid for producing DCVAXL for the trial patients and had all knowledge in-house. The mass manual production for DCVAXL certification would have taken CRL max 6 -9 months and would have cost max 25% of what NWBO is paying Advent.

LP has risked the treatment not coming to GBM patients more than once greed next to incompetence is just of those reasons.